Philip Darney, MD, MS

Philip Darney
Global Health Sciences Faculty Affiliate

Phone: 415-206-8358
UCSF Box: SFGH
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start
 		End
Stipend Grant United States Women's Health, Family Planning, Training and Capacity Building
A phase 3 multicenter open label study to evaluate the safety and efficacy of Levonorgestrel 90ug and ethinyl estradiol 20ug in a continuous daily regimen for oral contraception Wyeth United States Family Planning
Economic Opportunity for Zimbabwean Adolescent Orphans NIH National Institute of Child Health and Human Development Zimbabwe Sexually Transmitted Infections (STIs), HIV/AIDS
Misoprotsol versus Placebo with Laminaria for Cervical Ripening before Late Second Trimester Abortion United States Pharmacology and Drug Treatment, Family Planning
Phase 3, Evaluate the Return to Spontaneous Menses for Subjects Receiving Prior Treatment with a Daily Regimen of Daily Regimen of Levonorgestrel and Ethinyl Estradiol for Oral Contraception Wyeth United States Family Planning
Strengthening HIV Counselor Training in the Republic of Uganda AIDS Support Organization, The Uganda HIV/AIDS, Women's Health, Training International Scholars and Clinicians, Patient and Peer Education
Strengthening Teaching on Reproductive Health (RH) in Hue Medical Facility, Hue, Vietnam Pathfinder International Viet Nam Family Planning, Training and Capacity Building
Family PACT Evaluation Project California Department of Health Care Services United States
An Assessment of Burundian Refugees' Ideas on Family Planning in Kibondo, Tanzania Tanzania Family Planning, Access or Barriers to Care, Immigration and Migration
A randomized, open-label, comparative, multi-center trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estradiol Organon, Inc. United States Family Planning
Bayer 91555 FC Patch-low contraceptive study Bayer HealthCare Pharmaceuticals, Inc United States Family Planning
Phase 3, Randomized, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System (20 Mcg/Day) and Mirena® for Long-Term, Reversible Contraception up to Five Years Medicines360 United States Pharmacology and Drug Treatment, Family Planning
Family PACT Evaluation Project California Department of Public Health United States Women's Health, Family Planning, Adolescent Health
Contraceptive Clinical Trials Network - Female Sites [I] NIH National Institute of Child Health and Human Development United States Women's Health, Family Planning
Contraceptive Clinical Trials Network - Female Sites [II] NIH National Institute of Child Health and Human Development United States Women's Health, Family Planning
Fellowship in Family Planning Canada Women's Health, Family Planning, Residencies, Fellowships, and Postdoctoral Training
UCSF Family Planning Fellowship United States Family Planning, Residencies, Fellowships, and Postdoctoral Training
A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone Estetra SPRL United States Family Planning
Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of treatment effect on heavy menstrual bleeding Bayer HealthCare Pharmaceuticals, Inc United States Pharmacology and Drug Treatment, Women's Health, Family Planning